wichy-shutterstock-com-1

Wichy / Shutterstock.com

29 October 2015EuropePhilip Webber

Are the Broad Institute’s CRISPR patents too broad?

The ability of the CRISPR/Cas9 system to make precisely targeted mutations in genes, including human genes, has taken the biotech industry by storm. It has been described by some as being the most important development in biology since the discovery of the structure of DNA by Watson and Crick in 1953.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation and licensing: the CRISPR conundrum continues

4 June 2018 As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

article

CRISPR specialist raises $80m in funding

28 September 2018 US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

More on this story

article

CRISPR specialist raises $80m in funding

28 September 2018 US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

Regulation and licensing: the CRISPR conundrum continues

4 June 2018 As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

More on this story

article

CRISPR specialist raises $80m in funding

28 September 2018 US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

Let CRISPR/Cas9 battle commence

11 March 2016 The US Patent and Trademark Office has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

Regulation and licensing: the CRISPR conundrum continues

4 June 2018 As innovation in the CRISPR field continues across the world, questions are being asked about the role of regulating such a powerful tool, while discussions around licensing the technology continue, as LSIPR reports.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

CREATES Act unfairly tips the scales to generics

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages

LSPN Europe: Navigating the EPO and lessons from the UPC frontline

Paul Hastings reinforces London office with high-tech patent litigator

Comparing life sciences IP in Brazil and the US